Targeting the atypical chemokine receptor 2 (Ackr2) improves the benefit of anti-PD-1 immunotherapy in melanoma mouse model
{{output}}
Immune checkpoint blockade (ICB) therapies, such as anti-PD-1, have transformed cancer treatment, but many patients do not respond due to a non-inflammatory tumor microenvironment (TME). Here, we investigated the impact of targeting Atypical Chemokine Receptor... ...
